The Hepatitis A Gap: What a Small Welsh Outbreak Reveals About the Limits of Britain's Vaccination Strategy

There is a particular kind of scramble that happens when a health system meets a threat it has decided, in advance, not to plan for. This week at Barry Hospital in the Vale of Glamorgan, nurses are running a five-day emergency vaccination clinic for children aged five and under, trying to contain an outbreak whose source nobody has been able to identify. Eleven confirmed cases since December, all of the same strain, spreading quietly through a town of forty thousand people while officials waited to see whether it would burn itself out. It has not. So Public Health Wales has done what the UK's public health system does when hepatitis A takes hold: it has reached for reactive vaccination, because routine vaccination was never on offer.

That absence is the story here, more than the outbreak itself. Hepatitis A does not appear on the UK's routine childhood immunisation schedule. Children in Britain are protected against diphtheria, polio, hepatitis B, meningococcal disease and a long list of other pathogens as a matter of course, but hepatitis A is offered only to those judged at particular risk, travellers to endemic regions largely, or, as in Barry, once transmission is already under way. The Joint Committee on Vaccination and Immunisation revisits this position periodically and has not found the case for universal coverage compelling on cost effectiveness grounds. Case numbers have generally supported that judgement. The UK Health Security Agency records roughly four hundred infections a year in normal times, a manageable figure against the scale of the population.

But normal times are precisely what is in question. Case numbers jumped to 889 in 2024 before falling back to 95 in 2025, a swing large enough to suggest the disease's behaviour is not as settled as the routine schedule assumes. Meanwhile more than six thousand cases were confirmed across Europe last year, with clusters in Czechia, Slovakia, Austria and Hungary. A country that treats hepatitis A as a low priority domestically is not insulated from a continent where it is resurging, particularly given how easily the virus travels through food, water and the ordinary contact of households and schools. Barry's outbreak, still without a confirmed source months after the first cases appeared, is a reasonably direct illustration of what happens when a health protection team is left to trace transmission after the fact rather than blunt it in advance.

There is also a structural point that reaches beyond hepatitis A. This outbreak has been managed by Public Health Wales, working with Cardiff and Vale University Health Board and the local council, entirely outside the machinery that governs health protection in England. That is simply how devolution works, and nobody should expect otherwise. But it does mean that vaccination policy, outbreak thresholds and public communication can diverge meaningfully between nations that share a land border and, in places like the Severn crossing commuter corridor, a great deal of daily movement. When UKHSA and Public Health Wales each set their own tolerance for reactive versus routine intervention, the coherence of prevention policy across Britain becomes a matter of four separate judgement calls rather than one. That is a governance question worth asking honestly, not as an argument against devolution but as a reminder that infectious disease does not respect administrative boundaries even when policy does.

None of this amounts to a case for panic. Hepatitis A remains, for most people, an unpleasant illness rather than a dangerous one, and the clinicians in Barry are right to describe it that way. But the pattern is familiar to anyone who has watched NHS prevention policy over the past several years: capacity built for calm periods, stretched thin when contact tracing actually has to happen, and a public left to absorb the gap through emergency clinics rather than routine protection. Barry's outbreak will likely be contained within weeks. The underlying question, of whether the UK's threshold for routine hepatitis A vaccination still matches the disease's actual behaviour across Europe, deserves a harder look than a five-day clinic in south Wales can give it.